Nuzenio

Neurocrine Biosciences

Neurocrine Biosciences news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 11 publisher sources 100/100 entity strength

Latest news

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers - MarketBeatMarketBeat · Sat, 08 Aug 2026 07:41:34 GMTHow Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.stsimplywall.st · Sat, 08 Aug 2026 06:26:15 GMTThe BioPharm Brief: Fast Tracks, Triple Targets, and Second Chances - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 23:29:20 GMTNeurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance CanadaYahoo! Finance Canada · Fri, 07 Aug 2026 23:12:25 GMTNeurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 17:19:41 GMTNeurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study - AllSciAllSci · Fri, 07 Aug 2026 16:26:00 GMTNeurocrine starts Phase 1 trial for new obesity drug NBIP-'1968 targeting multiple metabolic pathways. - PluangPluang · Fri, 07 Aug 2026 12:49:32 GMTNeurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC - MarketBeatMarketBeat · Fri, 07 Aug 2026 10:55:54 GMT

Timeline

Sat, 08 Aug 2026 07:41:34 GMTNeurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers - MarketBeat
Sat, 08 Aug 2026 06:26:15 GMTHow Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Fri, 07 Aug 2026 23:29:20 GMTThe BioPharm Brief: Fast Tracks, Triple Targets, and Second Chances - BioPharm International
Fri, 07 Aug 2026 23:12:25 GMTNeurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Fri, 07 Aug 2026 17:19:41 GMTNeurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity - BioPharm International
Fri, 07 Aug 2026 16:26:00 GMTNeurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study - AllSci

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Neurocrine Biosciences.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

11 distinct publisher/source names are currently connected to this entity page.